Chulalongkorn University
chula.ac.thTotal trials
305
Active
49
Phase 3
26
Total enrollment
39,941
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 25 of 25 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Itopride HCI 50 mg | — | — | — | — | — | 1 | |
| Metoclopramide 10 mg ampoule | — | — | — | — | — | 1 | |
| Tranexamic Acid | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG | — | — | — | — | 2 | ||
| Switching to low dose emicizumab | — | — | — | — | — | 1 | |
| Drospirenone | — | — | — | — | 2 | ||
| Cabozantinib | — | — | — | — | — | 1 | |
| Transdermal Ethinyl Estradiol/Norelgestromin Patch | — | — | — | — | — | 1 | |
| B7H3 specific CAR T cell with IL-7Ra signaling domain | — | — | — | — | — | 1 | |
| Mulberry Leaf Extract | — | — | — | — | — | 1 | |
| B7H3-IL7Ra CAR-T cells | — | — | — | — | — | 1 | |
| CD19-IL7Ra CAR-T cells | — | — | — | — | — | 1 | |
| Chimeric Antigen Receptor T Cells | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Artificial saliva containing cumin and ginger extract | — | — | — | — | — | 1 | |
| Curcumin in Nanogels | — | — | — | — | — | 1 | |
| 0.1% Fluocinolone Acetonide Oral Paste | — | — | — | — | — | 1 | |
| Mulberry leaf extract 6 mg | — | — | — | — | — | 1 | |
| Mulberry leaf extract 12 mg | — | — | — | — | — | 1 | |
| Mulberry leaf extract 18 mg | — | — | — | — | — | 1 | |
| Local PEG4000 | — | — | — | — | — | 1 | |
| Commercial PEG4000 | — | — | — | — | — | 1 | |
| urea 40% cream | — | — | — | — | — | 1 | |
| Sericin extract and turmeric extract cream | — | — | — | — | — | 1 | |
| Triamcinolone acetonide 1% Cream | — | — | — | — | — | 1 |
Next readouts
- 2024-06-01
- 2024-12-30
- 2024-12-30
- 2025-06-30
- 2025-11-30
- 2025-12-31
- 2026-03-01
- 2026-03-01
- 2026-06-30
- 2026-06-30
Top conditions
- Allergic Rhinitis10
- Acute Kidney Injury7
- Healthy4
- Safety Issues4
- End-stage Renal Disease4
- Sepsis4
- Preterm Labor4
- Lupus Nephritis4
Frequently asked questions about Chulalongkorn University
- How many clinical trials does Chulalongkorn University have on ClinicalTrials.gov?
- Chulalongkorn University is listed as the lead sponsor on 305 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chulalongkorn University's trials are in Phase 3?
- 26 of Chulalongkorn University's trials are in Phase 3, spread across 25 active drug programs.
- What therapeutic areas does Chulalongkorn University focus on?
- Chulalongkorn University's most-studied conditions on ClinicalTrials.gov are Allergic Rhinitis, Acute Kidney Injury, Healthy, Safety Issues, End-stage Renal Disease.
- When are Chulalongkorn University's next clinical trial readouts?
- Chulalongkorn University has 10 upcoming primary-completion readouts tracked here; the soonest is “The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors”, expected around 2024-06-01.